MAPT and Alzheimer disease: Due to the demand for low-cost and high-accuracy diagnostic methods, biomarkers have evolved from traditional PET-MRI, Aβ protein concentration in CSF [48], and tau protein concentration [49] to the use of multimodal combined data [50] and EEG in diagnosing mild cognitive impairment (MCI) and AD [51].